BR112012021931A2 - composto, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de composto - Google Patents

composto, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de composto

Info

Publication number
BR112012021931A2
BR112012021931A2 BR112012021931A BR112012021931A BR112012021931A2 BR 112012021931 A2 BR112012021931 A2 BR 112012021931A2 BR 112012021931 A BR112012021931 A BR 112012021931A BR 112012021931 A BR112012021931 A BR 112012021931A BR 112012021931 A2 BR112012021931 A2 BR 112012021931A2
Authority
BR
Brazil
Prior art keywords
compound
treating
pharmaceutical composition
bacterial infection
present
Prior art date
Application number
BR112012021931A
Other languages
English (en)
Inventor
Deborah Zink
Helene Juteau
Joann Huber
Joel Robichaud
Karine Villeneuve
Kenneth Wilson
Michael J Salvatore Jr
Michel Gallant
Nancy Kevin
Patrick Beaulieu
Scott K Smith
Sherman T Waddell
Xin Gu
Yves Gareau
Original Assignee
Merck Canada Inc
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Canada Inc, Merck Sharp & Dohme filed Critical Merck Canada Inc
Publication of BR112012021931A2 publication Critical patent/BR112012021931A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composto, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de composto. a presente invenção obtém novos compostos de lipoglicopeptídeo que são inibidores de peptidase de sinal de tipo 1 (spsb). os compostos da presente invenção são úteis para o tratamento de várias doenças infecciosas relacionadas com bactérias, especialmente quando usados como potencializador de um antibiótico de <225>-lactana tal como imipenem e ertapenem. consequentemente, a presente invenção fornece um método para o tratamento de infecções relacionadas com bactérias usando os compostos aqui descritos, quer sozinhos quer combinação com um antibiótico de <255>-lactama.
BR112012021931A 2010-03-09 2011-03-04 composto, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de composto BR112012021931A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31205810P 2010-03-09 2010-03-09
PCT/US2011/027159 WO2011112441A1 (en) 2010-03-09 2011-03-04 Bridged lipoglycopeptides that potentiate the activity of beta-lactam antibacterials

Publications (1)

Publication Number Publication Date
BR112012021931A2 true BR112012021931A2 (pt) 2016-05-31

Family

ID=44563789

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012021931A BR112012021931A2 (pt) 2010-03-09 2011-03-04 composto, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de composto

Country Status (11)

Country Link
US (1) US20130244929A1 (pt)
EP (1) EP2544702A1 (pt)
JP (1) JP2013522204A (pt)
KR (1) KR20130028078A (pt)
CN (1) CN102939095A (pt)
AU (1) AU2011224710A1 (pt)
BR (1) BR112012021931A2 (pt)
CA (1) CA2791732A1 (pt)
MX (1) MX2012010381A (pt)
RU (1) RU2012142832A (pt)
WO (1) WO2011112441A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187524B2 (en) 2010-09-15 2015-11-17 The Scripps Research Institute Broad spectrum antibiotic arylomycin analogs
US10501493B2 (en) 2011-05-27 2019-12-10 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
KR20140132367A (ko) * 2012-02-16 2014-11-17 알큐엑스 파마슈티컬스, 인크. 선형 펩티드 항생제
EA201491646A1 (ru) * 2012-03-14 2015-03-31 Дзе Скриппс Рисёч Инститьют Аналоги антибиотика ариломицина широкого действия
BR112015011697A2 (pt) * 2012-11-21 2017-07-11 Rqx Pharmaceuticals Inc antibióticos macrocíclicos de amplo espectro
JP6178224B2 (ja) * 2013-12-03 2017-08-09 公益財団法人微生物化学研究会 併用抗メチシリン耐性黄色ブドウ球菌薬、及びβラクタム系抗生物質の抗菌活性増強剤
WO2015179441A2 (en) 2014-05-20 2015-11-26 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
WO2017024233A1 (en) * 2015-08-06 2017-02-09 The Scripps Research Institute Compositions and methods for identifying type i signal peptidase inhibitors
TWI725075B (zh) * 2015-11-20 2021-04-21 美商Ｒｑｘ製藥公司 巨環廣效抗生素
AU2016357926B2 (en) * 2015-11-20 2021-05-27 Genentech, Inc. Macrocyclic broad spectrum antibiotics
PE20191618A1 (es) * 2017-02-15 2019-11-05 Rqx Pharmaceuticals Inc Antibioticos macrociclicos de amplio espectro
PE20240066A1 (es) 2019-05-28 2024-01-11 Hoffmann La Roche Antibioticos macrociclicos de amplio espectro

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0968225A4 (en) * 1996-09-30 2000-11-08 Smithkline Beecham Plc NEW spsB
US6951840B2 (en) * 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
WO2003082909A1 (en) * 2002-03-29 2003-10-09 Wyeth Non-ribosomal peptide synthetases and associated biosynthetic genes
CN1839150A (zh) * 2003-07-17 2006-09-27 麦根克斯有限公司 脂肽抗菌衍生物组合物及其应用方法
EP2097440A4 (en) * 2006-12-22 2010-09-08 Targanta Therapeutics Inc ANTIBIOTICS BASED ON GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES PHOSPHONES AND THEIR USES IN THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
WO2008118784A1 (en) * 2007-03-23 2008-10-02 Targanta Therapeutics Corp. Glycopeptide and lipoglycopeptide antibiotics with improved solubility

Also Published As

Publication number Publication date
CN102939095A (zh) 2013-02-20
US20130244929A1 (en) 2013-09-19
CA2791732A1 (en) 2011-09-15
AU2011224710A1 (en) 2012-09-06
JP2013522204A (ja) 2013-06-13
KR20130028078A (ko) 2013-03-18
EP2544702A1 (en) 2013-01-16
RU2012142832A (ru) 2014-04-20
WO2011112441A1 (en) 2011-09-15
MX2012010381A (es) 2012-11-23

Similar Documents

Publication Publication Date Title
BR112012021931A2 (pt) composto, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de composto
EA201170772A1 (ru) Органические соединения
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
BRPI0922220B8 (pt) uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BR112018010962A2 (pt) composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de um composto.
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
CL2008002228A1 (es) Compuestos derivados de imidazopiridinonas, agonista de tlr7; procedimiento de preparacion; compuestos intermediarios; composiicon farmaceutica que los comprende; y uso en infecciones virales, bacterianas y fungicas.
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
MY153915A (en) Organic compounds
BR112014000665A2 (pt) composto, uso do mesmo, composição farmacêutica, agente antimicrobiano, e, método para previnir ou tratar uma infecção bacteriana
BRPI0809977A8 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
EA201000774A1 (ru) Ингибиторы бета-лактамазы
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
WO2009046314A3 (en) Moenomycin analogs, methods of synthesis, and uses thereof
BR112015011697A2 (pt) antibióticos macrocíclicos de amplo espectro
BRPI0907892A2 (pt) Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
EA201270590A1 (ru) Ингибиторы акт
NZ596628A (en) Ketolide compounds having antimicrobial activity
BR112014002958A2 (pt) &#34;3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso&#34;.
BR112018010255A2 (pt) antibióticos macrocíclicos de amplo espectro
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]